532 related articles for article (PubMed ID: 32993066)
1. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.
Rafael-Vidal C; Pérez N; Altabás I; Garcia S; Pego-Reigosa JM
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993066
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion therapy in rheumatic disease.
Edwards JC; Cambridge G; Leandro MJ
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of antinuclear antibodies in systemic rheumatic diseases.
Hietarinta M; Lassila O
Ann Med; 1996 Aug; 28(4):283-91. PubMed ID: 8862680
[TBL] [Abstract][Full Text] [Related]
5. [Basic immunologic indices and their significance in the diagnosis of rheumatic diseases. II. Analysis of immunologic indices in individual rheumatic diseases].
Timofeev VT
Revmatologiia (Mosk); 1983; (4):48-54. PubMed ID: 6366975
[No Abstract] [Full Text] [Related]
6. [Significance of antibodies against intermediate filaments in rheumatoid polyarthritis, chronic inflammatory rheumatism and connective tissue diseases].
Fabregas-Canales D; Meyer O; Haim T; Kuntz D
Rev Rhum Mal Osteoartic; 1989 Jan; 56(1):45-50. PubMed ID: 2471252
[No Abstract] [Full Text] [Related]
7. [Prospects of the use of cyclosporin A in rheumatic diseases].
Nasonov EL; Shtutman VZ; Nasonova VA
Klin Med (Mosk); 1994; 72(5):12-9. PubMed ID: 7853807
[No Abstract] [Full Text] [Related]
8. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis.
Jeong S; Yang D; Lee W; Kim GT; Kim HS; Ahn HS; Kim HJ
Semin Arthritis Rheum; 2018 Oct; 48(2):334-342. PubMed ID: 29609799
[TBL] [Abstract][Full Text] [Related]
9. Review: Innate Lymphoid Cells: Sparking Inflammatory Rheumatic Disease?
Wenink MH; Leijten EFA; Cupedo T; Radstake TRDJ
Arthritis Rheumatol; 2017 May; 69(5):885-897. PubMed ID: 28217945
[No Abstract] [Full Text] [Related]
10. [The role of interleukin-12 in immune-mediated rheumatic diseases].
Spadaro A; Scrivo R; Rinaldi T; Riccieri V; Sili Scavalli A; Taccari E; Valesini G
Reumatismo; 2002; 54(2):113-21. PubMed ID: 12105679
[TBL] [Abstract][Full Text] [Related]
11. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
De Jesus A; Talal N
Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028
[TBL] [Abstract][Full Text] [Related]
12. The immunology of rheumatoid diseases.
Koffler D
Clin Symp; 1979; 31(4):1-36. PubMed ID: 45382
[No Abstract] [Full Text] [Related]
13. Detection of anti-SSB antibodies in patients with rheumatic diseases.
Tang F; Dong Y; Zhang N
Chin Med Sci J; 1993 Mar; 8(1):55-8. PubMed ID: 8274726
[TBL] [Abstract][Full Text] [Related]
14. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
Narain S; Berman N; Furie R
Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.
Ferri C; Giuggioli D; Raimondo V; L'Andolina M; Tavoni A; Cecchetti R; Guiducci S; Ursini F; Caminiti M; Varcasia G; Gigliotti P; Pellegrini R; Olivo D; Colaci M; Murdaca G; Brittelli R; Mariano GP; Spinella A; Bellando-Randone S; Aiello V; Bilia S; Giannini D; Ferrari T; Caminiti R; Brusi V; Meliconi R; Fallahi P; Antonelli A;
Clin Rheumatol; 2020 Nov; 39(11):3195-3204. PubMed ID: 32852623
[TBL] [Abstract][Full Text] [Related]
16. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
17. ANAs in systemic rheumatic disease. Diagnostic significance.
Tan EM; Robinson CA; Nakamura RM
Postgrad Med; 1985 Sep; 78(3):141-2, 145-8. PubMed ID: 3875842
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile.
Spadaro A; Rinaldi T; Riccieri V; Taccari E; Valesini G
Clin Exp Rheumatol; 2002; 20(2):213-6. PubMed ID: 12051401
[TBL] [Abstract][Full Text] [Related]
19. Ganglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases.
Imamura M; Mukaino A; Takamatsu K; Tsuboi H; Higuchi O; Nakamura H; Abe S; Ando Y; Matsuo H; Nakamura T; Sumida T; Kawakami A; Nakane S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079137
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-9 and T helper type 9 cells in rheumatic diseases.
Ciccia F; Guggino G; Ferrante A; Cipriani P; Giacomelli R; Triolo G
Clin Exp Immunol; 2016 Aug; 185(2):125-32. PubMed ID: 27159882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
